C07K 14/5443
Il-15
Official title: {il-15}
C07K14/5443 (Il-15) appears on 482 US grants and 1,046 published applications in this corpus.
Search patents in C07K- Granted patents
- 482
- Published applications
- 1,046
- Assignees
- 379
- Inventors
- 1,685
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 0 |
| 2002 | 3 | 4 |
| 2003 | 4 | 5 |
| 2004 | 3 | 10 |
| 2005 | 1 | 13 |
| 2006 | 6 | 10 |
| 2007 | 9 | 7 |
| 2008 | 7 | 8 |
| 2009 | 6 | 9 |
| 2010 | 9 | 7 |
| 2011 | 8 | 10 |
| 2012 | 8 | 10 |
| 2013 | 9 | 8 |
| 2014 | 3 | 12 |
| 2015 | 7 | 9 |
| 2016 | 16 | 23 |
| 2017 | 7 | 20 |
| 2018 | 13 | 33 |
| 2019 | 24 | 43 |
| 2020 | 20 | 77 |
| 2021 | 48 | 112 |
| 2022 | 43 | 111 |
| 2023 | 51 | 135 |
| 2024 | 54 | 142 |
| 2025 | 79 | 130 |
| 2026 | 32 | 98 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Fusion polypeptide and polypeptide dimer, and use thereof29 Sep 2026US 12,747,275 B2Nanjing Normal University
- Development and use of interleukin 15 mutant polypeptide8 Sep 2026US 12,729,230 B2Suzhou Forlong Biotechnology Co., Ltd.
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Masking polypeptides, activatable cytokine constructs, and related compositions and methods24 Sep 2026US 2026/0285906 A1CytomX Therapeutics, Inc.
- Treatment of leukemia with engineered immune checkpoint inactivated car-nk cells or car t-cells24 Sep 2026US 2026/0286305 A1Albert-Ludwigs-Universität Freiburg Körperschaft des öffentlichen Rechts
Most cited
By later US patents
- System, apparatus, and method for reducing birefringence313US 6,491,391 B1E-Vision, LLC · 2002
- Optical lens system with electro-active lens having alterably different focal lengths247US 6,619,799 B1E-Vision, LLC · 2003
- Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells200US 6,653,104 B2Immunomedics, Inc. · 2003
- System, apparatus, and method for correcting vision using electro-active spectacles191US 6,517,203 B1E-Vision, LLC · 2003
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003